[HTML] acs.org

[HTML][HTML] FDA approval of aduhelm paves a new path for Alzheimer's disease

RE Tanzi - ACS chemical neuroscience, 2021 - ACS Publications
Aduhelm is an immunotherapy from Biogen that induces clearance of Alzheimer, s disease
(AD)-associated βamyloid deposits in the brain. Aduhelm was originally developed at the …
被引用次数：36 相关文章

[引用][C] FDA Approval of Aduhelm Paves a New Path for Alzheimer's Disease.

RE Tanzi - ACS Chemical Neuroscience, 2021 - europepmc.org
FDA Approval of Aduhelm Paves a New Path for Alzheimer's Disease. - Abstract - Europe
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …

[引用][C] FDA Approval of Aduhelm Paves a New Path for Alzheimer's Disease

RE Tanzi - ACS chemical neuroscience, 2021 - pubmed.ncbi.nlm.nih.gov